（文章来源：每日经济新闻） 每经AI快讯，2月4日，波士顿科学股价跌13%，创2020年3月以来最大盘中跌幅。 ...

Group 1 - The core point of the article is that Sino Medical has received the Medical Device Registration Certificate from the National Medical Products Administration of China for its drug-eluting stent system, which is a coronary stent product developed and manufactured by the company [2] Group 2 - The drug-eluting stent system is a self-developed product by the company [2] - The approval signifies a significant milestone for the company in the medical device industry [2] - This product is part of the company's efforts to expand its portfolio in the cardiovascular sector [2]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted earnings per share for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [19] - Full year 2025 adjusted earnings per share was $3.06, growing 22% versus 2024, also exceeding guidance [20] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [21] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% for the full year, with the brain franchise showing low double-digit growth [6] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Nalu Medical and Valencia Technologies, are aimed at enhancing the company's portfolio in neuromodulation and urology [24][25] - The company is focused on expanding its pain portfolio and enhancing operational efficiencies through new product launches and partnerships [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic growth of 10%-11% for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to maintain a strong market position despite competitive pressures, particularly in the EP segment [34][45] - Management highlighted the importance of upcoming clinical trial results, particularly for the Watchman product, which could significantly impact growth [81] Other Important Information - The company expects full-year free cash flow to be approximately $4.2 billion for 2026, with a target conversion rate of 70%-80% [24] - The adjusted tax rate for 2026 is forecasted to be around 12.5% [27] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [33][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [45] Question: Capacity issues in EP labs - Management acknowledged capacity constraints but emphasized ongoing efforts to build out ASCs and repurpose cath labs to alleviate wait times [72] Question: Confidence in long-term growth targets - Management remains confident in achieving 10%+ organic revenue growth through 2028, supported by strategic acquisitions and market leadership [86]

Group 1 - The core point of the article is that as of January 31, 2026, the number of shareholders for DiRi Medical is reported to be 15,812 [2]

Group 1 - The core viewpoint of the article is that Sanofi Bio (300298.SZ) is currently focused on developing its self-researched biosensing technology primarily for monitoring and managing diabetes and related chronic diseases [1] - The company has not yet ventured into the fields of neurointervention or brain-machine interfaces [1] - There are no ongoing preclinical studies specifically targeting neurochemical monitoring [1]

Core Viewpoint - Sanofi Bio (300298.SZ) is currently focused on self-developed biosensing technology primarily for monitoring and managing diabetes and related chronic diseases, with no involvement in neurointervention or brain-computer interface fields, nor has it conducted preclinical research specifically for neurobiochemical monitoring [1] Group 1 - The company is engaged in the development of biosensing technology [1] - The primary application of this technology is in diabetes and related chronic disease management [1] - There is no current involvement in neurointervention or brain-computer interface sectors [1]

Core Viewpoint - Boston Scientific's revenue growth forecast for 2026 is conservative, leading to a decline in stock price despite strong Q4 performance [1][2][3] Group 1: Financial Performance - The company reported adjusted earnings per share (EPS) of $0.80 for Q4, exceeding analyst expectations of $0.78 [3] - Revenue for Q4 reached $5.29 billion, slightly above the market forecast of $5.28 billion [3] Group 2: Future Guidance - For 2026, the company expects adjusted EPS to be between $3.43 and $3.49, with a midpoint of $3.46, which is below the analyst average estimate of $3.47 [1][2] - The organic revenue growth forecast for 2026 is projected at 10% to 11%, a decrease from the 15.8% growth rate in 2025 [3] - For Q1 2026, the expected adjusted EPS is between $0.78 and $0.80, compared to the analyst consensus of $0.79 [3] Group 3: Strategic Developments - The company is preparing to complete a $14.5 billion acquisition of Penumbra, announced last month [1][2]

Core Insights - Xishan Technology's strategy aligns with the newly introduced pricing guidelines for surgical and therapeutic auxiliary medical services, which focus on advanced medical technologies such as 3D printing and robotic surgery [2] Group 1: Pricing Guidelines - The "Guidelines for Pricing Projects of Surgical and Therapeutic Auxiliary Medical Services (Trial)" establishes 37 pricing projects centered on innovative medical technologies [2] - The guidelines specifically regulate the pricing policies for surgical power devices and energy surgical instruments, which include ultrasound knives and plasma knives, creating a more favorable market environment for related consumables [2] Group 2: Company Strategy - The company positions itself as a provider of comprehensive solutions for minimally invasive surgical tools, with product lines that include surgical power devices, endoscopic systems, and energy surgical equipment [2] - The company aims to deepen its consumable strategy, focusing on the widespread application of surgical power devices and the consumable nature of their surgical tips [2]

Core Viewpoint - The company is actively expanding its international market presence by increasing investment in international registration and promotion, with products now covering 46 countries and regions globally [2]. Group 1: International Market Expansion - The company plans to obtain CE-MDR certification for its surgical power device by the second half of 2025, which will significantly enhance future international product access and sales [2]. - The company aims to leverage the experience gained from obtaining CE certification to accelerate the registration of multiple products, including endoscopes and plasma devices, as well as related products in global markets [2]. - The company is establishing partnerships with distributors in target countries that have regional resources and channels aligned with its existing strengths, allowing these distributors to handle local market promotion and sales expansion [2]. Group 2: Strategic Development - The company will provide necessary product training and business guidance to distributors to ensure steady growth in international business [2]. - The company is focused on solidifying its technical foundation, obtaining key international certifications, building a global distribution network, and establishing a clear strategic path for long-term development in international markets [2]. - The company is committed to finding professional, high-quality, and suitable international partners to enhance the breadth and efficiency of market expansion, indicating a promising outlook for overseas market development [2].

Core Viewpoint - The company Meihao Medical (301363) has shown mixed financial performance, with revenue growth but a decline in net profit, indicating potential challenges in profitability despite stable revenue growth [2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [2]. - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [2]. - The net profit excluding non-recurring items was 203 million yuan, down 17.85% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 93.90 million yuan, an increase of 5.89% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 92.70 million yuan, up 9.56% year-on-year [2]. - The company's debt ratio stands at 11.43%, with investment income of 4.90 million yuan and financial expenses of -27.39 million yuan [2]. - The gross profit margin is reported at 39.34% [2]. Market Activity - As of February 4, 2026, Meihao Medical's stock closed at 32.02 yuan, with a slight increase of 0.25% [1]. - The trading volume was 91,300 hands, with a total transaction value of 289 million yuan [1]. - The net inflow of main funds was 1.9749 million yuan, accounting for 0.68% of the total transaction value [1]. - Retail investors showed a net inflow of 9.0572 million yuan, representing 3.14% of the total transaction value [1]. - Over the past 90 days, seven institutions have rated the stock as a buy, with an average target price of 24.57 yuan [3].